Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Emergent BioSolutions Inc.
  6. Financials
    EBS   US29089Q1058

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 3 0202 7854 7492 378--
Entreprise Value (EV)1 3 7023 4285 0022 7492 1242 378
P/E ratio 48,6x51,9x15,8x10,4x14,3x16,0x
Yield ------
Capitalization / Revenue 3,86x2,52x3,05x1,41x1,65x1,88x
EV / Revenue 4,73x3,10x3,22x1,63x1,47x1,88x
EV / EBITDA 18,6x12,3x7,94x5,43x5,20x-
Price to Book 3,00x2,55x3,29x1,34x1,18x-
Nbr of stocks (in thousands) 50 94551 62452 99953 799--
Reference price (USD) 59,354,089,644,244,244,2
Announcement Date 02/21/201902/20/202002/18/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 7821 1061 5551 6891 4441 265
EBITDA1 199280630506409-
Operating profit (EBIT)1 89,8114434341287240
Operating Margin 11,5%10,3%27,9%20,2%19,9%19,0%
Pre-Tax Profit (EBT)1 81,577,4407304257209
Net income1 62,754,5305230174157
Net margin 8,01%4,93%19,6%13,6%12,0%12,4%
EPS2 1,221,045,674,263,102,76
Dividend per Share ------
Announcement Date 02/21/201902/20/202002/18/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 343398329620302340
EBITDA1 12449,5-3,30332--
Operating profit (EBIT)1 95,414,5-34,726689,590,3
Operating Margin 27,8%3,65%-10,5%42,9%29,6%26,6%
Pre-Tax Profit (EBT)1 85,27,20-45,525779,480,2
Net income1 69,74,60-32,717059,360,0
Net margin 20,3%1,16%-9,94%27,4%19,6%17,6%
EPS2 1,280,09-0,613,470,260,67
Dividend per Share ------
Announcement Date 04/29/202107/29/202111/04/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 682643254371--
Net Cash position1 ----254-
Leverage (Debt / EBITDA) 3,43x2,30x0,40x0,73x-0,62x-
Free Cash Flow1 -30,3101395-276438265
ROE (Net Profit / Equities) 12,4%14,5%33,4%21,1%7,84%-
Shareholders' equity1 5043769121 0912 220-
ROA (Net Profit / Asset) 7,25%6,68%16,3%11,4%4,78%-
Assets1 8658161 8752 0113 637-
Book Value Per Share2 19,721,127,333,037,4-
Cash Flow per Share ------
Capex1 72,186,914117210080,0
Capex / Sales 9,22%7,86%9,07%10,2%6,92%6,32%
Announcement Date 02/21/201902/20/202002/18/2021---
1 USD in Million
2 USD
Analysis
Exclusive: Tens of millions of J&J COVID-19 shots sit at Baltimore factory - sources
Key data
Capitalization (USD) 2 378 438 935
Net sales (USD) 1 555 400 000
Number of employees 2 200
Sales / Employee (USD) 707 000
Free-Float 88,6%
Free-Float capitalization (USD) 2 106 661 219
Avg. Exchange 20 sessions (USD) 55 120 573
Average Daily Capital Traded 2,32%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA